Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company AVI BioPharma
With that in mind, let's take a closer look at AVI's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Bothell, Wash. (1980)|
|Market Cap||$209.0 million|
|Trailing-12-Month Revenue||$47.0 million|
|Management||CEO Christopher Garabedian (since 2011)
CFO J. David Boyle, II (since 2008)
|Return on Equity (average, past 3 years)||(151.1%)|
|Cash/Debt||$39.9 million / $1.8 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 13% of the 194 members who have rated AVI believe the stock will underperform the S&P 500 going forward.
I find myself gingerly handing out red thumbs to the baby bios that all started running up in late December without catalysts, hoping I'm not pushing against the edge of some ridiculous new biotech bubble.
Over the last five years AVI has been a consistent underperformer, with slow progress and little clinical success from their antisense pipeline. The current projects in clinical development bear little resemblance to the coronary stent and hepatitis C-related compounds I remember from 2007. ... I don't see any clear pathway toward profitability in the foreseeable future through the antiviral compounds that remain in phase I.
If you want to retire rich, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled this special free report for investors to uncover this stock today. It is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
Why Sarepta Therapeutics Stock Doubled in 2017
Sarepta's new Duchenne muscular dystrophy drug burst onto the scene in 2017.
Here's What Caused Sarepta Therapeutics to Shoot 13% Higher In November
The company's well on its way to transforming muscular dystrophy treatment.
What Caused Sarepta Therapeutics to Rally 12.6% in September
Optimism is building for the company's potential to treat more Duchenne muscular dystrophy patients.